DK200000375U1 - Polypeptidsammensætninger med forbedret stabilitet. - Google Patents

Polypeptidsammensætninger med forbedret stabilitet.

Info

Publication number
DK200000375U1
DK200000375U1 DK200000375U DKBA200000375U DK200000375U1 DK 200000375 U1 DK200000375 U1 DK 200000375U1 DK 200000375 U DK200000375 U DK 200000375U DK BA200000375 U DKBA200000375 U DK BA200000375U DK 200000375 U1 DK200000375 U1 DK 200000375U1
Authority
DK
Denmark
Prior art keywords
glycerin
compositions
polypeptide
chemical stability
improved stability
Prior art date
Application number
DK200000375U
Other languages
Danish (da)
English (en)
Inventor
Michael Rosario Defelippis
Michael Allen Dobbins
Alby David Sharknas
Alex Mark Prokai
Vincent Rinella Junior Joseph
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27341882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK200000375(U1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from JP37720899A external-priority patent/JP2001181203A/ja
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DK200000375U1 publication Critical patent/DK200000375U1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK200000375U 1999-12-16 2000-12-14 Polypeptidsammensætninger med forbedret stabilitet. DK200000375U1 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17113599P 1999-12-16 1999-12-16
JP37720899A JP2001181203A (ja) 1999-12-16 1999-12-28 安定性が改良されたポリペプチド組成物
US18103000P 2000-02-08 2000-02-08

Publications (1)

Publication Number Publication Date
DK200000375U1 true DK200000375U1 (da) 2001-03-16

Family

ID=27341882

Family Applications (1)

Application Number Title Priority Date Filing Date
DK200000375U DK200000375U1 (da) 1999-12-16 2000-12-14 Polypeptidsammensætninger med forbedret stabilitet.

Country Status (15)

Country Link
EP (1) EP1242121B1 (de)
JP (1) JP2003523972A (de)
CN (1) CN1409640A (de)
AT (1) ATE288765T1 (de)
AU (1) AU777570B2 (de)
BR (1) BR0016334A (de)
CA (1) CA2394213A1 (de)
DE (2) DE60018105T2 (de)
DK (1) DK200000375U1 (de)
EA (1) EA004631B1 (de)
ES (1) ES2236010T3 (de)
IL (1) IL150129A0 (de)
PL (1) PL355378A1 (de)
PT (1) PT1242121E (de)
WO (1) WO2001043762A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1412384T3 (da) 2001-06-28 2008-04-28 Novo Nordisk As Stabil formulering af modificeret GLP-1
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
JP2006505562A (ja) * 2002-10-17 2006-02-16 アルカーメス コントロールド セラピューティクス，インコーポレイテッド 持続放出組成物の放出プロフィールの調節方法
EP1559433A4 (de) * 2002-10-22 2009-11-04 Dainippon Sumitomo Pharma Co Stabilisierte zusammensetzung
JP2007524592A (ja) 2003-06-03 2007-08-30 ノボ・ノルデイスク・エー／エス 安定化された薬学的ペプチド組成物
KR101308912B1 (ko) 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 안정화된 약학적 펩티드 조성물
CA2598632A1 (en) 2003-11-20 2005-06-16 Solvay (Societe Anonyme) Process for producing dichloropropanol
KR101243648B1 (ko) 2003-11-20 2013-03-14 노보 노르디스크 에이/에스 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
EP1789434B1 (de) 2004-08-31 2013-11-20 Novo Nordisk A/S Verwendung von tris(hydroxymethyl)-aminomethan zur stabilisierung von peptiden, polypeptiden und proteinen
EP1817048B1 (de) 2004-11-12 2014-02-12 Novo Nordisk A/S Stabile formulierungen insulinoptropischer peptide
DE502007003700D1 (de) * 2006-07-27 2010-06-24 Cognis Ip Man Gmbh Verfahren zur Herstellung von Glycerin
TWI478875B (zh) 2008-01-31 2015-04-01 Solvay 使水性組成物中之有機物質降解之方法
EP2910571B1 (de) 2008-03-18 2016-10-05 Novo Nordisk A/S Proteasestabilisierte, acylierte insulinanaloga
FR2935968B1 (fr) 2008-09-12 2010-09-10 Solvay Procede pour la purification de chlorure d'hydrogene
RS56632B1 (sr) 2008-10-17 2018-03-30 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
CN102711804B (zh) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
AU2010317995B2 (en) 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
JP2011195557A (ja) * 2010-02-24 2011-10-06 Kyorin Pharmaceutical Co Ltd 糖アルコールの選択方法
JP6199186B2 (ja) 2010-08-30 2017-09-20 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病の治療用の医薬の製造のためのａｖｅ００１０の使用
DK2433651T3 (da) 2010-09-03 2013-04-08 Aug Hedinger Gmbh & Co Kg Fremgangsmåde til bestemmelse af aldehyder og ketoner i glycerin
US9309209B2 (en) 2010-09-30 2016-04-12 Solvay Sa Derivative of epichlorohydrin of natural origin
US9097692B2 (en) 2010-10-01 2015-08-04 Aug. Hedinger Gmbh & Co. Kg Method for quantitatively determining impurities in glycerin
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CN104364260B (zh) 2012-04-11 2017-02-22 诺和诺德股份有限公司 胰岛素制剂
MX2017007699A (es) 2014-12-12 2017-09-18 Sanofi Aventis Deutschland Formulacion de proporcion fija de insulina glargina/lixisenatida.
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
MA49116A (fr) 2016-12-16 2020-03-25 Novo Nordisk As Compositions pharmaceutiques contenant de l'insuline
HRP20240485T1 (hr) 2017-08-24 2024-07-05 Novo Nordisk A/S Pripravci glp-1 i njihova upotreba
CA3159054A1 (en) * 2019-12-06 2021-06-10 Mary S. MORRIS Methods and compositions for the treatment and prevention of type 1 diabetes
US20230082544A1 (en) 2020-02-18 2023-03-16 Novo Nordisk A/S Pharmaceutical formulations
WO2022076385A1 (en) * 2020-10-08 2022-04-14 Dr. Mary Morris & Associates, Llc Methods and compositions for the treatment and prevention of type 1 diabetes
WO2024081659A1 (en) * 2022-10-13 2024-04-18 Archer Daniels Midland Company Purification of glycerin as excipient in parenteral pharmaceutical applications

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA49890C2 (uk) * 1996-06-20 2002-10-15 Ново Нордіск А/С Водна інсулінова композиція, парентеральна фармацевтична композиція та спосіб поліпшення хімічної стабільності інсулінової композиції

Also Published As

Publication number Publication date
AU2049301A (en) 2001-06-25
EP1242121B1 (de) 2005-02-09
PT1242121E (pt) 2005-05-31
EA004631B1 (ru) 2004-06-24
DE20021079U1 (de) 2001-03-22
ES2236010T3 (es) 2005-07-16
PL355378A1 (en) 2004-04-19
DE60018105D1 (de) 2005-03-17
CN1409640A (zh) 2003-04-09
JP2003523972A (ja) 2003-08-12
IL150129A0 (en) 2002-12-01
DE60018105T2 (de) 2005-12-29
AU777570B2 (en) 2004-10-21
WO2001043762A2 (en) 2001-06-21
WO2001043762A3 (en) 2002-01-10
EA200200684A1 (ru) 2003-02-27
CA2394213A1 (en) 2001-06-21
EP1242121A2 (de) 2002-09-25
BR0016334A (pt) 2002-09-10
ATE288765T1 (de) 2005-02-15

Similar Documents

Publication Publication Date Title
DK200000375U1 (da) Polypeptidsammensætninger med forbedret stabilitet.
SE0002102D0 (sv) Chemical compound
TR200402703T4 (tr) Çözünür CTLA4 mutantları ve bunların kullanımı.
TR200201874T2 (tr) Proteaz inhibitörleri olarak yeni bileşikler ve bileşimler.
PT1413582E (pt) Pirrolobenzodiazepinas dimericas
DK0912176T3 (da) Anvendelse af pyridylalkan-, pyridylalken- og/eller pyridylalkynsyreamider til behandling af tumorer eller immunosuppression
ATE380822T1 (de) Funf-helix protein
MY133969A (en) Indoloquinazolinones
TR199802079T2 (xx) D-Manitol ve haz�rlanmas�.
BR0009421A (pt) Inibidores de ligação lfa-1 aos icams e uso dos mesmos
BR0115121A (pt) Compostos n-((1,2,4)triazoloazinil)tiofenossulfonamida como herbicidas
AU2001269575A1 (en) Nucleic acid sequences and proteins involved in cellular senescence
TR200501541T2 (tr) Leu-hirudinin e.coli ile kültür ortamında ayrışarak üretilmesinin sinyal sekansları
DE60001850D1 (de) Chalcon coumarine
TR200101493T2 (tr) Eletriptan hidrobromid monohidrat
TR200001080T2 (tr) 2 ile ikame edilmiş 1,2-Benisotiyazol türevleri ve bunların serrotonın antagonistleri
TR200401875T2 (tr) Endoparazit öldürücü bileşimler
BR0207033A (pt) variantes de amina oxidase ap1
EA200400393A1 (ru) Антитела против каспазы-8, их получение и применение
ATE341342T1 (de) Ace inhibitor-vasopressin antagonist kombinationen
TR200102815T1 (tr) Displazili dokunun tespiti için kullanılacak in vivo lekeleme bileşik ve metodları.
WO2001070384A3 (de) Verwendung von duftalkoholalkoxylaten als solubilisierhilfsmittel
IT1319871B1 (it) Uso degli ultrasuoni al fine di migliorare la conservazione del lattenello stabilimento di produzione.
ITFO20000026V0 (it) Uso degli ultrasuoni al fine di migliorare la conservazione del lattenello stabilimento di produzione.
ITRM20000523A0 (it) Uso di cellule ingegnerizzate di lievito per l'ottenimento di biosensori, e biosensori cosi' ottenuti.

Legal Events

Date Code Title Description
URF Utility model: application refused